Vimarsana
Biggest News Aggregation in the World

Certain Relapsed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Certain Relapsed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Certain Relapsed Today - Breaking & Trending Today

ASH 2021 | Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a China Study Demonstrating Complete Responses - Vimarsana News

ASH 2021 | Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a China Study Demonstrating Complete Responses

Published: December 14, 2021

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Source: prnewswire.com
Related Topics:
United StatesHong KongWestern AustraliaAscentage PharmaYifan ZhaiJianxiang WangPrnewswire Ascentage PharmaMajor NationalMd Anderson Cancer CenterAmerican Society Of HematologyChina National Medical Products AdministrationNational Major New Drug DiscoveryDana Farber Cancer InstituteAmerican SocietyVice PresidentChinese AcademyMedical Science Hematology HospitalHematology ResearchChief Medical OfficerCertain RelapsedHematologic MalignanciesPoster PresentationLymphocytic LeukemiaOverall ResponseOrally Administered Lisaftoclax
ASH 2021 | Ascentage Pharma to Release Latest Data from Two Studies of Its Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a Chinese Study Demonstrating Complete Response - Vimarsana News

ASH 2021 | Ascentage Pharma to Release Latest Data from Two Studies of Its Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a Chinese Study Demonstrating Complete Response

Published: November 5, 2021

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Source: prnewswire.com
Related Topics:
United StatesHong KongAscentage PharmaYifan ZhaiAmerican Society Of HematologyMajor NationalEuropean UnionMd Anderson Cancer CenterDana Farber Cancer InstituteAmerican SocietyEfficacy ResultsNovel Third GenerationKinase InhibitorResistant Chronic Myeloid LeukemiaPivotal PhaseTyrosine Kinase InhibitorAccelerated Phase Chronic Myeloid LeukemiaBridging StudyOrally Administered OlverembatinibRefractory Chronic Myeloid LeukemiaCertain RelapsedHematologic MalignanciesSingle AgentRefractory Chronic LymphocyticSmall Lymphocytic Lymphoma